The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 283.00
Bid: 279.00
Ask: 283.00
Change: -7.00 (-2.41%)
Spread: 4.00 (1.434%)
Open: 285.00
High: 285.00
Low: 279.00
Prev. Close: 290.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

HUTCHMED to Host Company Update

17 May 2021 07:00

RNS Number : 8027Y
Hutchmed (China) Limited
17 May 2021
 

Press Release

 

Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors

 

 - HUTCHMED will hold a webcast on Wednesday, May 26 at 8 a.m. EDT to provide updates on recent progress and upcoming milestones -

 

Hong Kong, Shanghai & Florham Park, NJ - Monday, May 17, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM) today announces that it will host a virtual investor update event on Wednesday, May 26, 2021. Members of the senior management team will provide updates on product launches in China, preparations for US commercialization, R&D, as well as a review of new data presented at the 2021 ASCO Annual Meeting.

 

Analysts and investors are invited to join a conference call and audio webcast presentation. The event will take place at 8:00 a.m. Eastern Daylight Time / 1:00 p.m. British Summer Time (BST) / 8:00 p.m. Hong Kong Time (HKT) on Wednesday, May 26. A first Q&A session will immediately follow the prepared remarks. For Asian investors, a recording of the webcast will be available for viewing the following morning and a second Q&A session will start at 12:00 noon HKT on Thursday, May 27.

 

The event will be webcast live and can be accessed at www.hutch-med.com/event. Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter for approximately 90 days.

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM: HCM) (formerly Hutchison China MediTech) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,200 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first two oncology drugs now approved and launched. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the U.S. Securities and Exchange Commission and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

 

 

CONTACTS

 

Investor Enquiries

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

Media Enquiries

 

Americas - Brad Miles,Solebury Trout

+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw,FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)HUTCHMED@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi,Brunswick

+852 9850 5033 (Mobile) / +852 9783 6894 (Mobile)HUTCHMED@brunswickgroup.com

Nominated Advisor

Freddy Crossley / Atholl Tweedie,Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAARMATMTBBMJB
Date   Source Headline
23rd Jul 20151:01 pmRNSNotification of major interest in shares
23rd Jul 20159:01 amRNSMitsui exchanges shares in Hutchison MediPharma
17th Jul 20157:00 amRNSInvention patent granted for SXBXP
6th Jul 20157:00 amRNSNotice of Announcement of 2015 Interim Results
29th Jun 20157:00 amRNSBlocklisting Six Monthly Return
1st Jun 20157:00 amRNSSavolitinib preliminary Phase Ib data presented
13th May 20157:00 amRNSFruquintinib results trigger payments from Lilly
30th Apr 20157:00 amRNSTotal Voting Rights
24th Apr 201512:40 pmRNSResult of AGM
22nd Apr 201511:23 amRNSDirector/PDMR Shareholding
16th Apr 20151:19 pmRNSDirector's Shareholding
13th Apr 20158:07 amRNSDirector's Shareholding
8th Apr 20158:18 amRNSDirectors' Shareholding
1st Apr 20153:48 pmRNSDirectors Shareholding
1st Apr 20152:32 pmRNSExercise of Options
30th Mar 20157:00 amRNSTrial of fruquintinib achieves primary endpoint
23rd Mar 20157:00 amRNSNotice of AGM
18th Mar 20157:08 amRNSNotification of Major Interest in Shares
6th Mar 20157:06 amRNSPatient enrolment completion for Phase II study
26th Feb 20157:00 amRNSFinal Results
29th Jan 20157:00 amRNSDistribution Agreement for Seroquel in China
26th Jan 20157:00 amRNSNotice of Results
31st Dec 20147:00 amRNSTotal Voting Rights
29th Dec 20147:00 amRNSBlocklisting Six Monthly Return
15th Dec 20147:00 amRNSInitiation of fruquintinib Phase III study
31st Oct 20147:03 amRNSTotal Voting Rights
7th Oct 20147:00 amRNSDrug R&D Update Briefing
1st Oct 20147:00 amRNSCo-promotion agreement with Merck Serono
19th Sep 20149:13 amRNSHolding(s) in Company
21st Aug 20147:00 amRNSPatient enrolment in Phase II study completed
13th Aug 20147:00 amRNSHMPL-004 Interim Analysis
29th Jul 20147:00 amRNSInterim Results
30th Jun 20147:00 amRNSBlocklisting Interim Review
30th Jun 20147:00 amRNSTotal Voting Rights
26th Jun 20147:00 amRNSNotice of Results
25th Jun 20147:00 amRNSChi-Med Refinancing of Existing Loan Facility
18th Jun 20147:00 amRNSStart of Phase I clinical trial with HMPL-523
5th Jun 20147:00 amRNSInitiation of fruquintinib Phase II study
4th Jun 20141:52 pmRNSDirector's Shareholding
3rd Jun 20143:23 pmRNSExercise of Options
30th May 20149:10 amRNSGains rights to six prescription drug products
23rd May 20147:00 amRNSInitiation of Phase II Study in Renal Cancer
22nd May 20147:00 amRNSPhase I data to be presented at ASCO
8th May 201411:54 amRNSResult of AGM
17th Apr 20147:00 amRNSChi-Med and Sinopharm Deal Approved
4th Apr 20147:00 amRNSInitiation of Phase II study in colorectal cancer
4th Apr 20147:00 amRNSPresentations at the 2014 AACR Annual Meeting
28th Mar 20147:00 amRNS2013 Annual Report and Notice of AGM
18th Feb 20147:00 amRNSFinal Results
13th Feb 20148:14 amRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.